Orthocell appoints second Canadian distributor for flagship nerve repair device

• Orthocell appoints its second distributor in US$75 million Canadian market for flagship nerve repair device Remplir
• New distributor granted exclusive rights to distribute Remplir across all Canadian provinces outside of Alberta and British Columbia
• Orthocell now has full national distribution coverage across Canada, strengthening position in key market

Special Report: Orthocell (ASX:OCC) has strengthened its North American footprint with the appointment of a second distributor in Canada, securing full national coverage for its flagship nerve repair device Remplir in the country’s ~US$75 million market.

The new Ontario-based distributor has been granted exclusive rights to sell Remplir across all Canadian provinces except Alberta and British Columbia, which continue to be managed by Orthocell’s existing partner.

The addition means Remplir will now be available to hospitals and surgeons across all provinces, from major metropolitan centres to regional healthcare facilities.

The move represents another important milestone in Orthocell’s global commercial rollout of Remplir, which received Health Canada Medical Device Licence (MDL) approval in April, well ahead of schedule after its February submission.

Well established networks

The new distributor brings deep experience in the nerve, spine and orthopaedic implant sectors and has well-established relationships across Canada’s public and private hospital networks.

The distribution team for Remplir will comprise six product managers driving a team of 30 sales agents, providing the scale and reach needed to accelerate adoption of the product in both urban and rural markets.

Orthocell completed initial launch activities for Remplir in Canada at the Annual Meeting of the American Society for Surgery of the Hand, held in Vancouver in October.

The company expects first Canadian sales to be recorded this quarter following positive engagement from clinicians during the event.

Future launch and marketing efforts in Canada will be managed by Orthocell’s US-based marketing and medical education teams, bringing significant efficiencies to the company’s North American rollout.

The company also received US FDA clearance in April for Remplir, paving the way for its commercial distribution in the world’s largest nerve repair market, estimated at US$1.6 billion.

Remplir’s US rollout continues to gain traction, with in-country representatives working closely with distributors to secure hospital approvals, onboard surgeons and establish active accounts, with initial surgical cases building.

‘Opening up the entire Canadian market’

CEO and managing director Paul Anderson said the appointment marked a major step forward in Orthocell’s North American growth strategy.

“We’re very pleased to expand our Canadian distributor presence beyond Alberta and BC with this new appointment opening up the entire Canadian market,” Anderson said.

“Our focus remains on rolling out Remplir in the jurisdictions where we have regulatory approvals.

“The most efficient pathway to market is through in-country distributors that hold direct relationships with our end customers – surgeons and hospitals.”

Anderson said each new distributor appointment was an important step, initiating targeted sales and marketing efforts in their territories and bringing Orthocell closer to generating new revenue streams.

“We’re building significant global momentum with our distributor relationships globally, led by our US portfolio covering 25 states alongside recent appointments in Hong Kong and Canada, as well as our longer-term relationships with DVT in Australia and Singapore.

With more than $50 million in cash and no debt, Orthocell is well funded as it continues to execute its international commercialisation strategy and drive a step-change in revenue in FY26.

This article was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.